Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma — IRIS

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Clinical Trial

Official title:
Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone

Status Completed

Clinical Trial Summary

Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.

Clinical Trial Description

Preliminary data suggest intralesional rituximab is able to revert resistance to systemic rituximab in patients with CD20+ indolent lymphoma of the conjunctiva, and the addition of autologous serum seems to exhibit a synergistic effect on tumor regression. These two main aspects will be assessed in this trial. ;

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell, Marginal Zone
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

Clinical Trial Details

NCT number	NCT01514344
Study type	Interventional
Source	IRCCS San Raffaele
Contact
Status	Completed
Phase	Phase 2
Start date	December 2011
Completion date	October 2019

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT02494700` - Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma	Phase 2
	Enrolling by invitation	`NCT01302912` - Lymphoma in the Orbit	Phase 4